Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy

Clinical and Experimental Nephrology

Volumn 15, Issue 5, 2011, Pages 634-640

  Ohishi, Waka ^a   Chayama, Kazuaki ^b  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

De novo HBV infection; Hepatitis B virus reactivation; Nucleoside analogue; Rituximab; Steroid

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ALLERGY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; COLLAGEN DISEASE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; JAPAN; NEPHROTIC SYNDROME; NONHUMAN; REVIEW; RISK FACTOR; SCREENING TEST; SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA, VIRAL; GLUCOCORTICOIDS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; LYMPHOMA; VIRUS ACTIVATION;

EID: 80755153653     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0464-7     Document Type: Review

References (58)

1. W Ohishi S Fujiwara JB Cologne G Suzuki M Akahoshi N Nishi, et al. 2008 Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study Cancer Epidemiol Biomarkers Prev 17 846 854 18398026 10.1158/1055-9965.EPI-07-2806 1:CAS:528:DC%2BD1cXkslGqtbs%3D (Pubitemid 351536415)
2. WM Lee 1997 Hepatitis B virus infection N Engl J Med 337 1733 1745 9392700 10.1056/NEJM199712113372406 1:STN:280:DyaK1c%2FktFyjtA%3D%3D (Pubitemid 27527771)
3. JR Wands CM Chura FJ Roll WC Maddrey 1975 Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders Gastroenterology 68 105 112 1054319 1:STN:280:DyaE2M7htleksw%3D%3D
4. AS Lok RH Liang EK Chiu KL Wong TK Chan D Todd 1991 Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 182 188 1983820 1:STN:280: DyaK3M%2FmtVSiuw%3D%3D
5. P Seth AA Alrajhi I Kagevi MA Chaudhary E Colcol E Sahovic M Aljurf M Gyger 2002 Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease Bone Marrow Transpl 30 189 194 10.1038/sj.bmt.1703614 1:STN:280:DC%2BD38vjtFyrtw%3D%3D (Pubitemid 34993859)
6. PS Parfrey RD Forbes TA Hutchinson JG Beaudoin WD Dauphinee DJ Hollomby, et al. 1984 The clinical and pathological course of hepatitis B liver disease in renal transplant recipients Transplantation 37 461 466 6375001 10.1097/00007890-198405000-00008 1:STN:280:DyaL2c3isFSmsw%3D%3D (Pubitemid 14119045)
7. PS Parfrey RD Forbes TA Hutchinson S Kenick D Farge WD Dauphinee, et al. 1985 The impact of renal transplantation on the course of hepatitis B liver disease Transplantation 39 610 615 3890290 10.1097/00007890-198506000-00007 1:STN:280:DyaL2M3hvF2gsg%3D%3D (Pubitemid 15066950)
8. AJ Demetris R Jaffe DG Sheahan J Burnham J Spero S Iwatsuki, et al. 1986 Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection Am J Pathol 125 161 172 3535528 1:STN:280:DyaL2s%2Fks1ejsQ%3D%3D (Pubitemid 17183769)
9. D Samuel A Bismuth D Mathieu JL Arulnaden M Reynes JP Benhamou, et al. 1991 Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients Lancet 337 813 815 1672913 10.1016/0140-6736(91)92515-4 1:STN:280:DyaK3M7psVChuw%3D%3D
10. S Todo AJ Demetris D Van Thiel L Teperman JJ Fung TE Starzl 1991 Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease Hepatology 13 619 626 2010156 1:STN:280:DyaK3M7osVOisw%3D%3D
11. D Samuel R Muller G Alexander L Fassati B Ducot JP Benhamou, et al. 1993 Liver transplantation in European patients with the hepatitis B surface antigen N Engl J Med 329 1842 1847 8247035 10.1056/NEJM199312163292503 1:STN:280:DyaK2c%2Fmslaisw%3D%3D (Pubitemid 23360483)
12. CK Hui WW Cheung HY Zhang WY Au YH Yueng AY Leung, et al. 2006 Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy Gastroenterology 131 59 68 16831590 10.1053/j.gastro. 2006.04.015 1:CAS:528:DC%2BD28XnvF2gsL0%3D
13. W Yeo TC Chan NW Leung WY Lam FK Mo MT Chu, et al. 2009 Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 605 611 19075267 10.1200/JCO.2008.18.0182 1:CAS:528:DC%2BD1MXivFyju7s%3D
14. T Umemura E Tanaka K Kiyosawa H Kumada Japan de novo Hepatitis B Research Group 2008 Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan Clin Infect Dis 47 e52 e56 18643758 10.1086/590968
15. H Tubouchi H Kumada K Kiyosawa S Mochida I Sakaida E Tanaka, et al. 2009 Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection-Joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis Acta Hepatol Japonica 50 38 42 10.2957/kanzo.50.38
16. H Yotsuyanagi C Okuse K Yasuda E Orito S Nishiguchi J Toyoda, et al. 2005 Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan J Med Virol 77 39 46 16032734 10.1002/jmv.20411 1:CAS:528:DC%2BD2MXps1Cgs7Y%3D (Pubitemid 41076474)
17. Y Suzuki M Kobayashi K Ikeda F Suzuki Y Arase N Akuta, et al. 2005 Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan J Med Virol 76 33 39 15779048 10.1002/jmv.20320 (Pubitemid 40446452)
18. M Kobayashi K Ikeda Y Arase F Suzuki N Akuta T Hosaka, et al. 2008 Change of hepatitis B virus genotypes in acute and chronic infections in Japan J Med Virol 80 1880 1884 18814241 10.1002/jmv.21309
19. TL Fong AM Di Bisceglie MA Gerber JG Waggoner JH Hoofnagle 1993 Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B Hepatology 18 1313 1318 8244254 10.1002/hep.1840180605 1:CAS:528:DyaK2cXnsVKhsQ%3D%3D (Pubitemid 23348415)
20. Y Murakami M Minami Y Daimon T Okanoue 2004 Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen J Med Virol 72 203 214 14695661 10.1002/jmv.10547 (Pubitemid 38020547)
21. H Kumada K Ikeda A Yoshida S Seto T Tsukada M Kojima, et al. 1987 Short-term prednisolone for inducing seroconversion from hepatitis B e antigen to antibody along with clinical improvement in patients with chronic active hepatitis type B Jpn J Med 26 217 222 3626161 10.2169/internalmedicine1962.26. 217 1:STN:280:DyaL2szht1GmsQ%3D%3D (Pubitemid 17137807)
22. Y Arase K Ikeda N Murashima K Chayama A Tsubota I Koida, et al. 1999 Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis B Am J Gastroenterol 94 11 3304 3309 10566734 10.1111/j.1572-0241.1999.01542.x 1:STN:280:DC%2BD3c%2FjtFSisg%3D%3D
23. N Akuta F Suzuki A Tsubota Y Arase Y Suzuki T Someya, et al. 2002 Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial-CSWT with and without follow-up interferon-alpha therapy Dig Dis Sci 47 405 414 11855559 10.1023/A:1013742727165 1:CAS:528: DC%2BD38XitVSgsb0%3D (Pubitemid 34124003)
24. JD Ashwell FW Lu MS Vacchio 2000 Glucocorticoids in T cell development and function Annu Rev Immunol 18 309 345 10837061 10.1146/annurev.immunol.18.1. 309 1:CAS:528:DC%2BD3cXjs1Gmsbo%3D (Pubitemid 30365383)
25. R Tur-Kaspa RD Burk Y Shaul DA Shafritz 1986 Hepatitis B virus DNA contains a glucocorticoid-responsive element Proc Natl Acad Sci USA 83 1627 1631 3006059 10.1073/pnas.83.6.1627 1:CAS:528:DyaL28XitVWgs7o%3D (Pubitemid 16018617)
26. YF Liaw 1998 Hepatitis viruses under immunosuppressive agents J Gastroenterol Hepatol 13 14 20 9737566 10.1111/j.1440-1746.1998.tb00539.x 1:CAS:528:DyaK1cXisVWktbw%3D
27. S Kusumoto Y Tanaka M Mizokami R Ueda 2009 Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma Int J Hematol 90 13 23 19544079 10.1007/s12185-009-0359-5 1:CAS:528:DC%2BD1MXotV2qt7o%3D
28. S Kusumoto Y Tanaka R Ueda M Mizokami 2011 Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy J Gastroenterol 46 9 16 20924616 10.1007/s00535-010-0331-4 1:CAS:528:DC%2BC3MXmsFSjsw%3D%3D
29. J Golay L Zaffaroni T Vaccari M Lazzari GM Borleri S Bernasconi, et al. 2000 Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 3900 3908 10845926 1:CAS:528:DC%2BD3cXktFCht7o%3D (Pubitemid 30412866)
30. H Taji Y Kagami Y Okada M Andou Y Nishi H Saito, et al. 1998 Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody Jpn J Cancer Res 89 748 756 9738982 10.1111/j.1349-7006. 1998.tb03280.x 1:CAS:528:DyaK1cXltlCjurY%3D (Pubitemid 28401161)
31. D Shan JA Ledbetter OW Press 1998 Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1644 1652 9473230 1:CAS:528:DyaK1cXht12gsbk%3D (Pubitemid 28110329)
32. K Benz J Dötsch W Rascher D Stachel 2004 Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy Pediatr Nephrol 19 794 797 15071769 10.1007/s00467-004-1434-z (Pubitemid 38931165)
33. M Nakayama K Kamei K Nozu K Matsuoka A Nakagawa M Sako, et al. 2008 Rituximab for refractory focal segmental glomerulosclerosis Pediatr Nephrol 23 481 485 17973121 10.1007/s00467-007-0640-x
34. RD Gilbert E Hulse S Rigden 2006 Rituximab therapy for steroid-dependent minimal change nephrotic syndrome Pediatr Nephrol 21 1698 1700 16932900 10.1007/s00467-006-0228-x (Pubitemid 44390835)
35. H François E Daugas A Bensman P Ronco 2007 Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations Am J Kidney Dis 49 158 161 17185157 10.1053/j.ajkd.2006.10.015 (Pubitemid 44932200)
36. MS Dai TY Chao WY Kao RY Shyu TM Liu 2004 Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP Ann Hematol 83 769 774 15338194 10.1007/s00277-004-0899-y 1:CAS:528:DC%2BD2cXpt1Wqsbk%3D (Pubitemid 39485548)
37. W Yeo PJ Johnson 2006 Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy Hepatology. 43 209 220 16440366 10.1002/hep.21051 1:CAS:528:DC%2BD28XhvVSgu7o%3D
38. P Ostuni C Botsios L Punzi P Sfriso S Todesco 2003 Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate Ann Rheum Dis 62 686 687 12810441 10.1136/ard.62.7.686 1:STN:280:DC%2BD3s3ot1Gnug%3D%3D (Pubitemid 36760576)
39. M Esteve C Saro F González-Huix F Suarez M Forné JM Viver 2004 Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis Gut 53 1363 1365 15306601 10.1136/gut.2004.040675 1:STN:280:DC%2BD2cvgt1Crsg%3D%3D (Pubitemid 39120128)
40. P Suwannalai P Auethavekiat U Udomsubpayakul S Janvitayanujit 2009 The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital Int J Rheum Dis 12 118 124 20374328 10.1111/j.1756-185X.2009.01393.x
41. T Matsumoto H Marusawa M Dogaki Y Suginoshita T Inokuma 2010 Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection Liver Int 30 1241 1242 20345703 10.1111/j.1478-3231.2010.02238.x
42. W Ohishi K Chayama 2009 Current treatment for chronic hepatitis B in Japan Clin J Gastroenterol 2 325 330 10.1007/s12328-009-0100-1
43. H Kumada T Okanoue M Onji H Moriwaki N Izumi E Tanaka, et al. 2010 Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan Hepatol Res 40 1 7 20156295 10.1111/j.1872-034X.2009.00633.x
44. CL Lai J Dienstag E Schiff NW Leung M Atkins C Hunt, et al. 2003 Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 687 696 12627352 10.1086/368083 1:CAS:528:DC%2BD3sXjtVKqtbk%3D (Pubitemid 36337972)
45. DJ Tenney RE Rose CJ Baldick KA Pokornowski BJ Eggers J Fang, et al. 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy Hepatology 49 1503 1514 19280622 10.1002/hep.22841 1:CAS:528:DC%2BD1MXlslKmurw%3D
46. A Ahmed EB Keeffe 1999 Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection Am J Gastroenterol 94 249 251 9934765 10.1111/j.1572-0241.1999.00808.x 1:CAS:528:DyaK1MXhtV2gt7o%3D (Pubitemid 29063477)
47. W Yeo JL Steinberg JS Tam PK Chan NW Leung KC Lam, et al. 1999 Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy J Med Virol 59 263 269 10502254 10.1002/(SICI)1096-9071(199911)59: 3<263::AID-JMV1>3.0.CO;2-X 1:CAS:528:DyaK1MXmvV2jtbc%3D (Pubitemid 29468064)
48. FL Clark MW Drummond S Chambers BA Chapman WN Patton 1998 Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma Ann Oncol 9 385 387 9636828 10.1023/A:1008206519571 1:STN:280:DyaK1czgtVCmtQ%3D%3D (Pubitemid 28273030)
49. M Picardi C Selleri G De Rosa A Raiola L Pezzullo B Rotoli 1998 Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation Bone Marrow Transpl 21 1267 1269 10.1038/sj.bmt.1701266 1:STN:280:DyaK1czjslKiuw%3D%3D (Pubitemid 28318756)
50. P Colson P Borentain D Coso C Chabannon C Tamalet R Gérolami 2008 Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma Br J Haematol 143 148 150 18710387 10.1111/j.1365-2141.2008.07318.x
51. W Yeo PK Chan WM Ho B Zee KC Lam KI Lei, et al. 2004 Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy J Clin Oncol 22 927 934 14990649 10.1200/JCO.2004.05.161 1:CAS:528:DC%2BD2cXpsVKisrg%3D (Pubitemid 41103605)
52. G Rossi A Pelizzari M Motta M Puoti 2001 Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy Br J Haematol 115 58 62 11722410 10.1046/j.1365-2141.2001.03099.x 1:CAS:528:DC%2BD3MXotFWmsLw%3D (Pubitemid 32995093)
53. O Shibolet Y Ilan S Gillis A Hubert D Shouval R Safadi 2002 Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers Blood 100 391 396 12091327 10.1182/blood.V100.2.391 1:CAS:528:DC%2BD38XlsVWgsbc%3D (Pubitemid 34761098)
54. GK Lau HH Yiu DY Fong HC Cheng WY Au LS Lai, et al. 2003 Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 1742 1749 14724827 10.1053/j.gastro.2003.09.026 1:CAS:528:DC%2BD2cXhtVOruw%3D%3D (Pubitemid 37500439)
55. LH Katz A Fraser A Gafter-Gvili L Leibovici R Tur-Kaspa 2008 Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis J Viral Hepat 15 89 102 18184191 1:STN:280:DC%2BD1c%2Fit1ahtg%3D%3D
56. R Loomba A Rowley R Wesley TJ Liang JH Hoofnagle F Pucino, et al. 2008 Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 519 528 18378948 (Pubitemid 351665421)
57. R Okita M Takahashi H Narahara Y Sanada M Okada Y Kawakami, et al. 2009 Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy Clin J Gastroenterol 2 214 217 10.1007/s12328-009-0063-2
58. M Watanabe A Shibuya J Takada Y Tanaka Y Okuwaki T Minamino, et al. 2010 Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients Eur J Intern Med 21 4 333 337 20603047 10.1016/j.ejim.2010.04.010 1:CAS:528:DC%2BC3cXosVKjt7k%3D